

COVID Deaths Plunge after Major World City Introduces Ivermectin

Authorities create home-treatment-kit for 22 million-strong population

By Art Moore

Global Research, June 01, 2021

WND News Center 31 May 2021

Region: <u>Latin America & Caribbean</u>

Theme: Science and Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at @crg globalresearch.

A citywide initiative in Mexico City to prescribe ivermectin to COVID-19 patients resulted in a plunge in hospitalizations and deaths, two studies found.

Hospitalizations were down by as much as 76%, according to research by the Mexican Digital Agency for Public Innovation, Mexico's Ministry of Health and the Mexican Social Security Institute, according to a TrialSiteNews report highlighted by LifeSiteNews.

Earlier this month, as <u>WND reported</u>, a significant decrease in cases in India coincided with the national health ministry's promotion of ivermectin and hydroxychloroquine treatments.

In Mexico City, after a spike in cases in December, the city's Ministry of Health created a home-treatment kit for residents. The city's metro population is 22 million.

At the time, the head of the Mexico City Ministry of Health, Oliva López, said told reporters her agency had determined "that there is enough evidence to use in people positive for SARS-CoV-2, even without symptoms, some drugs such as ivermectin and azithromycin."

Beginning Dec. 29, people who tested positive for COVID from an antigen test and who were experiencing at least mild symptoms began receiving one of the government's ivermectin-based treatment kits, TrialSiteNews reported.

The Mexican government then began a study to track the impact of the early treatment of COVID with ivermectin on the city's population.

The study tracked 200,000 people, dividing in two cohorts — those who received ivermectin and those who did not.

Are governments preventing the public from getting treatments that actually help defeat COVID?

Through a phone-call-based monitoring system and hospital data on admissions for

COVID-19, the researchers found a reduction of between 52% and 76% in hospitalizations for those who took ivermectin compared to those who did not.

The government's findings were corroborated by Dr. Juan J. Chamie-Quintero, a senior data analyst at private Colombian university EAFIT.

He found that excess deaths in the city dropped sharply only a few weeks after the ivermectin treatments began.

Chamie-Quintero also conducted a study in Peru, where the government approved ivermectin as a treatment for the virus in May 2020.

In the 24 Peruvian states that adopted early use of ivermectin treatment, excess deaths plummeted on average by 59% just 30 days after the peak death rate. And it had dropped 75% after 45 days in those over 60 years old.

'Large, statistically significant reductions in mortality'

Worldwide, more than 50 peer-reviewed studies have shown the effectiveness of ivermectin as a treatment and prophylaxis against COVID-19.

A study by the American Journal of Therapeutics that analyzed 18 randomized controlled treatment trials found ivermectin elicited "large, statistically significant reductions in mortality, time to clinical recovery, and time to viral clearance" in COVID patients.

The study concluded that "the many examples of ivermectin distribution campaigns leading to rapid population-wide decreases in morbidity and mortality indicate that an oral agent effective in all phases of COVID-19 has been identified."

In February, a peer-reviewed study found that invermectin reduces coronavirus infections, hospitalizations and deaths by about 75%.

Ivermectin, in more than 30 trials around the world, causes "repeated, consistent, large magnitude improvements in clinical outcomes' at all stages of the disease," according to the study, which was published in the U.S. journal Frontiers of Pharmacology.

The evidence is so strong, the researchers believe, the anti-parasitic drug should become a standard therapy everywhere, hastening global recovery.

"The data is overwhelming – we are in a pandemic, and this is an incredibly effective way to combat it. If we use ivermectin widely, our societies can open up," said study co-author Professor Paul Marik, director of emergency and pulmonary care at Eastern Virginia Medical School.

A previous study by Professor Andrew Hill of Liverpool University also found ivermectin cuts death rates by about 75%.

'Inaction in front of mounting evidence'

Dr. Pierre Kory, the chief medical officer of the <u>Front Line Covid-19 Critical Care Alliance</u>, is known for his congressional testimony about the effectiveness of ivermectin. In a live Zoom conference May 13, he showed the promising data from various states in India in the two

weeks after ivermectin was promoted.

See Kory's presentation: https://youtu.be/byFEU1A5MRY (note: youtube has already removed this video)

In a Senate hearing in December, Kory presented evidence that ivermectin prevents infection and saves lives.

"Although we, like many, are extremely encouraged by the apparent successes in developing effective vaccines, we also are dismayed at the near complete absence of guidance and research on effective early, at-home, or preventative treatment options apart from vaccines, a reality we find unconscionable," he said in his statement.

Kory said he and his colleagues are "worried that if our call to action is not followed through, confidence in our health care leaders and agencies will be irreparably tarnished."

"Inaction in front of mounting evidence of safety and effectiveness during a catastrophic pandemic may also compromise widespread vaccination support," he warned.

"We will look back to the impact that actions versus inaction had on the U.S. and the globe two months from now," Kory said. "If we do nothing, the present trend will continue. History will judge."

See testimony of a life saved by ivermectin:

Politicization of treatments

Dr. Harvey Risch, a professor of epidemiology at the Yale School of Public Health and Yale School of Medicine, is one of many health experts who decry the politicization of COVID-19 treatments such as ivermectin and hydroxychloroguine.

"You can hardly believe what anybody says anymore," Risch <u>said in an interview in December with Fox News' Laura Ingraham</u>. "We've lost 300,000 lives in the United States because our government has basic told everyone to go home, stay home, and if you can't breathe, go to the hospital."

That's not a form of treatment, he said, "it's what we call therapeutic nihilism."

He said the federal government, through the FDA, CDC and National Institutes of Health, have misrepresented the benefits of the drugs.

"These are drugs that everywhere else in the world they are being used very effectively," he said.

Risch contends the COVID-19 mortality rate is five times lower in the Third World "because that's all they can afford to do."

"And we're here twiddling our thumbs and telling everyone to stay home. It's absurd," he said.

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums, etc.

The original source of this article is <u>WND News Center</u> Copyright © <u>Art Moore</u>, <u>WND News Center</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Art Moore

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: $\underline{publications@globalresearch.ca}$